🎩✅CVRX - The strategic value of Barostim could be significantly higher than the current valuation

A few facts that are difficult to ignore right now:
• CVRx reported **$15.7M in Q2 2026 revenue**, up 16% YoY, with an **87% gross margin**. U.S. revenue grew 21%.
• In May, **Humana** introduced Medicare Advantage coverage for Barostim. Today, CVRx announced that **Devoted Health** also issued a coverage policy, effective July 17, 2026. Together, Humana and Devoted represent approximately **21% of Medicare Advantage enrollment**. Devoted covers approximately **466,000 members across 29 states**, including patients enrolled in BENEFIT-HF.
• At the Canaccord conference, CEO Kevin Hykes discussed **5–7 strategic companies** for which Barostim could fit very naturally into their existing portfolios. This does **not** mean those companies are currently making offers, but it does show that management sees meaningful strategic value in the technology.
• And now the most interesting development: shareholder **Jorey Chernett**, who owns more than **5.5% of CVRx**, has called on the Board to immediately retain an independent financial advisor and begin a strategic alternatives process, with a **sale of the company to a strategic buyer as the priority outcome**.
In my view, the four most logical strategic buyers are:
✅**Johnson & Johnson, Boston Scientific, Medtronic and Abbott.**
This is based on strategic fit — **not** an assertion that any of them are currently in negotiations.
J&J is particularly interesting because its subsidiary JJDC already owns **4,024,861 CVRx shares, approximately 15.4% of the company**.
**What about a potential acquisition price?**
With roughly 26.5M shares:
**$10 = \~$265M equity value**
**$15 = \~$398M equity value**
**$20 = \~$530M equity value**
At $15/share, an acquirer would be paying roughly **6× annual revenue**, which does not look unreasonable for a differentiated commercial MedTech asset with an 87% gross margin, expanding payer coverage, and significant potential market expansion through BENEFIT-HF.
My view:
**$13–17 = reasonable base range for a genuine strategic sale process.**
**$18–22 = possible if multiple strategic buyers compete.**
This is not a prediction that a deal is already in the works. But the combination of a **5.5% activist shareholder, expanding reimbursement, Barostim’s strategic value, BENEFIT-HF, and J&J’s 15.4% ownership** makes CVRx much more interesting as an M&A situation than simply an undervalued medical-device company.
**For me, $15 is not an unrealistic target if a genuine strategic sale process begins.**